- cost-effectiveness/benefit assessments will only be disease-specific
- price (price cut-off point) is dependent on existing competitors and incremental "effect"
- there is apparently no discussion about thresholds, such as QALYs etc.
- assessment will be supplemented by budget-impact analysis
For an English version of the method paper, click here.
I am certain there will be lots of discussions among all stakeholders and it remains to be seen how that turns out in Germany. I will be posting the upcoming news on the matter, stay tuned!